Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Loss of clinical response (at 52 weeks, HBI change from baseline of less than 4 points and a total score of less than 7 points) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher loss of clinical response (at 52 weeks, HBI change from baseline of… compared with biosimilar (low certainty).
1 finding from 1 review
Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review